Publications in collaboration with researchers from Hospital Universitario de la Princesa (1)

2012

  1. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

    Anti-Cancer Drugs, Vol. 23, Núm. 2, pp. 239-246